在资本市场和并购交易中,我是创业者与投资人值得信赖的顾问与合作伙伴。

经验

IGM Biosciences – $201 Million IPO

September 18, 2019

Cooley advised underwriters on IGM Biosciences’ $201.3 million initial public offering of 12,578,125 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Jefferies, Piper Jaffray, Stifel, Nicolaus & Company and Guggenheim Securities acted as joint book-running managers for the offering. IGM Biosciences’ securities now trade on the Nasdaq Global Select Market under the symbol “IGMS.” Partners Jonie Kondracki, Charlie Kim, Dave Peinsipp and Will Cai led the Cooley team.

Related contacts

Jonie Ing Kondracki
Partner, 旧金山
Charlie Kim
Partner, 圣地亚哥
David Peinsipp
Partner, 旧金山
蔡华
合伙人, 香港
Natalie Karam
Partner, 帕罗奥图
Daniel Hutchins
Associate, 帕罗奥图

Related Practices & Industries

Phathom Pharmaceuticals - $209 Million IPO

October 30, 2019

Cooley advised underwriters on Phathom Pharmaceuticals' $209 million initial public offering of 10,997,630 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Needham & Company acted as the lead manager for the offering. Goldman Sachs & Co. LLC, Jefferies and Evercore ISI acted as joint book-running managers for the offering. Phathom Pharmaceuticals' securities now trade on the Nasdaq Global Market under the symbol “PHAT.” Charlie Kim, Sean Clayton, Jonie Kondracki and Will Cai led the Cooley team.

Related contacts

Charlie Kim
Partner, 圣地亚哥
Jonie Ing Kondracki
Partner, 旧金山
蔡华
合伙人, 香港

Related Practices & Industries

Fangdd $78 Million – IPO

November 6, 2019

Cooley advised Fangdd on its $78 million initial public offering of 6,000,000 American depositary shares, each representing 25 class A ordinary shares. The underwriters have a 30-day option to purchase up to 900,000 additional shares. The transaction represents Cooley’s first completed IPO out of its newly launched Hong Kong office. Partner Will Cai led the Cooley team advising Fangdd. Founded in 2011 by former real estate agents Yi Duan and Xi Zeng, Fangdd now trades its securities on the Nasdaq Global Select Market under the symbol “DUO.”

Read more

Related contacts

蔡华
合伙人, 香港
袁晓通
资深顾问律师, 北京
张捷
合伙人, 香港
Aaron Pomeroy
Partner, 科罗拉多
Francis Wheeler
Partner, 科罗拉多
Charlie Kim
Partner, 圣地亚哥
Darren DeStefano
Partner, 雷斯顿
余仙
香港办事处主管合伙人, 香港
刘颖
律师, 香港

Related Practices & Industries

EHang Holdings - $40 Million IPO

December 12, 2019

Cooley advised EHang Holdings on its $40 million initial public offering of 3,200,000 shares of American Depository Shares. EHang Holdings, whose securities now trade on the Nasdaq Global Market under the symbol “EH,” is an autonomous aerial vehicle (“AAV”) technology platform company. Partners Will Cai, Charlie Kim, and Dave Peinsipp led the Cooley team.

Related contacts

蔡华
合伙人, 香港
Charlie Kim
Partner, 圣地亚哥
David Peinsipp
Partner, 旧金山

Related Practices & Industries

ORIC Pharmaceuticals - $138 Million IPO

April 24, 2020

Cooley advised ORIC Pharmaceuticals on its $138 million initial public offering of 8,620,000 shares of common stock, including full exercise of the underwriter's option to purchase additional shares. ORIC Pharmaceuticals, whose securities now trade on the Nasdaq Global Select Market under the symbol “ORIC”, is a developer of novel therapies intended to overcome resistance in cancer. Partners Charlie Kim, Sean Clayton, Kristin VanderPas and Will Cai led the Cooley team.

Related contacts

Charlie Kim
Partner, 圣地亚哥
Kristin VanderPas
Partner, 旧金山
蔡华
合伙人, 香港

Related Practices & Industries

查看全部